December 15, 2025 · Form 4 insider transaction
Oltmans Curtis Gale sold 3,452 shares of Fulcrum Therapeutics, Inc. at $12.92 per share, a transaction worth $44.6K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.; Includes 10,252 shares that were previously acquired under the Issuer's employee stock purchase plan.